Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus

Antiviral Research

Volumn 96, Issue 1, 2012, Pages 59-64

  Akbar, Sheikh Mohammad Fazle ^a   Chen, Shiyi ^b   Al Mahtab, Mamun ^c   Abe, Masanori ^b   Hiasa, Yoichi ^b   Onji, Morikazu ^b  

^a Shinagawa ku   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

Author keywords

Chronic hepatitis B; Dendritic cells; Hepatitis B core antigen; Immune therapy

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; DENDRITIC CELL; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINATION;

ANIMALS; CELL PROLIFERATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; IMMUNOTHERAPY; LIVER; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; SPLEEN; T-LYMPHOCYTES;

HEPATITIS B VIRUS; MURINAE; MUS MUSCULUS;

EID: 84865283534     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.07.011     Document Type: Article

References (29)

1. Aguilar J.C., Lobaina Y., Muzio V., García D., Pentón E., Iglesias E., Pichardo D., Urquiza D., Rodríguez D., Silva D., Petrovsky N., Guillén G. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol. Cell. Biol. 2004, 82:539-546.
2. Akbar S.M., Furukawa S., Horiike N., Abe M., Hiasa Y., Onji M. Safety and immunogenecity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B. J. Viral. Hepat. 2010, 18:408-414.
3. Akbar S.M., Yoshida O., Chen S., Aguilar A.J., Abe M., Matsuura B., Hiasa Y., Onji M. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection. Antivir. Ther. 2010, 15:887-895.
4. Akbar S.M., Al-Mahtab M., Rahman S., Aguilar J.C., Onji M., Mishiro S. Therapeutic potential of a novel therapeutic vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) administered through mucosal and parental route in patients with chronic hepatitis B. Hepatology 2010, 52(Suppl.):438A-439A.
5. Araki K., Miyazaki J., Hino O., Tomita N., Chisaka O., Matsubara K., Yamamura K. Expression and replication of hepatitis B virus genome in transgenic mice. Proc. Natl. Acad. Sci. USA 1989, 86:207-211.
6. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 2005, 5:296-306.
7. Bertoletti A., Maini M.K. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. Curr. Opin. Microbiol. 2000, 3:387-392.
8. Chen S., Akbar S.M., Abe M., Hiasa Y., Onji M. Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin. Exp. Immunol. 2011, 166:134-142.
9. Heathcote J., McHutchison J., Lee S., Tong M., Benner K., Minuk G., Wright T., Fikes J., Livingston B., Sette A., Chestnut R. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 1999, 30:531-536. The CY1899 T Cell Vaccine Study Group.
10. Hoa P.T., Huy N.T., Thu le T., Nga C.N., Nakao K., Eguchi K., Chi N.H., Hoang B.H., Hirayama K. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob. Agents Chemother. 2009, 53:5134-5140.
11. Lee B.O., Tucker A., Frelin L., Sallberg M., Jones J., Peters C., Hughes J., Whitacre D., Darsow B., Peterson D.L., Milich D.R. Interaction of the hepatitis B core antigen and the innate immune system. J. Immunol. 2009, 182:6670-6681.
12. Liaw Y.F. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009, 29(Suppl 1):100-107.
13. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
14. Lin S.M., Sheen I.S., Chien R.N., Chu C.M., Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999, 29:971-975.
15. Lobaina Y., Palenzuela D., Pichardo D., Muzio V., Guillén G., Aguilar J.C. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol. Immunol. 2005, 42:289-294.
16. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
17. Luo J., Li J., Chen R.L., Nie L., Huang J., Liu Z.W., Luo L., Yan X.J. Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine 2010, 28:2497-2504.
18. Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S., King A.S., Herberg J., Gilson R., Alisa A., Williams R., Vergani D., Naoumov N.V., Ferrari C., Bertoletti A. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 2000, 191:1269-1280.
19. Miyake T., Akbar S.M., Yoshida O., Chen S., Hiasa Y., Matsuura B., Abe M., Onji M. Impaired dendritic cell functions disrupt antigen-specific adaptive immune responses in mice with non alcoholic fatty liver disease. J. Gastroenterol. 2010, 45:859-867.
20. Pol S., Driss F., Michel M.L., Nalpas B., Berthelot P., Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994, 344(8918):342.
21. Pol S., Nalpas B., Driss F., Michel M.L., Tiollais P., Denis J., Brécho C. Multicenter study group. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. 2001, 34:917-921.
22. Shamliyan T.A., MacDonald R., Shaukat A., Taylor B.C., Yuan J.M., Johnson J.R., Tacklind J., Rutks I., Kane R.L., Wilt T.J. Antiviral therapy for adults with chronic hepatitis B: A systemic review for a National Institute of Health consensus development conference. Ann. Intern. Med. 2009, 150:111-124.
23. Sprengers D., Janssen H.L. Immunomodulatory therapy for chronic hepatitis B virus infection. Fund Clin. Pharmacol. 2005, 19:17-26.
24. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
25. van der Molen R.G., Sprengers D., Binda R.S., de Jong E.C., Niesters H.G., Kusters J.G., Kwekkeboom J., Janssen H.L. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004, 40:738-746.
26. Vandepapelière P., Lau G.K., Leroux-Roels G., Horsmans Y., Gane E., Tawandee T., Merican M.I., Win K.M., Trepo C., Cooksley G., Wettendorff M., Ferrari C. Therapeutic HBV Vaccine Group of Investigators. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007, 25:8585-8597.
27. Wang X.Y., Zhang X.X., Yao X., Jiang J.H., Xie Y.H., Yuan Z.H., Wen Y.M. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine 2010, 28:8169-8174.
28. Wilt T.J., Shamliyan T., Shaukat A., Taylor B.C., MacDonald R., Yuan J.M., Johnson J.R., Tacklind J., Rutks I., Kane R.L. Management of chronic hepatitis B. Evid. Rep. Technol. Assess (Full Rep.) 2008, 174:1-671.
29. Yoshida O., Akbar S.M., Chen S., Miyake T., Abe M., Hiasa Y., Murakami H., Onji M. Regulatory natural killer cells in murine liver and their immunosuppressive capacity. Liver Int. 2010, 30:906-912.